[NESTLE] YoY Quarter Result on 30-Jun-2016 [#2]

Stock
[NESTLE] NESTLE (M) BHD
Announcement Date
22-Aug-2016
Admission Sponsor
-
Sponsor
-
Financial Year
31-Dec-2016
Quarter
30-Jun-2016 [#2]
Profit Trend
QoQ- -14.45%
YoY- 52.37%
Quarter Report
Latest QR
Upcoming QR
NESTLE's Result
NESTLE's Financial Summary
View:
Show?
Quarter Result
30/06/19 30/06/18 30/06/17 30/06/16 30/06/15 30/06/14 30/06/13 CAGR
Revenue 1,335,706 1,309,059 1,283,630 1,237,165 1,142,901 1,270,164 1,214,222 1.60%
PBT 199,112 214,408 212,542 223,897 159,556 155,057 174,180 2.25%
Tax -42,225 -48,246 -50,472 -35,100 -35,653 -36,579 -33,942 3.70%
NP 156,887 166,162 162,070 188,797 123,903 118,478 140,238 1.88%
-
NP to SH 156,887 166,162 162,070 188,797 123,903 118,478 140,238 1.88%
-
Tax Rate 21.21% 22.50% 23.75% 15.68% 22.35% 23.59% 19.49% -
Total Cost 1,178,819 1,142,897 1,121,560 1,048,368 1,018,998 1,151,686 1,073,984 1.56%
-
Net Worth 715,224 736,330 712,879 722,259 691,775 705,844 705,844 0.22%
Dividend
30/06/19 30/06/18 30/06/17 30/06/16 30/06/15 30/06/14 30/06/13 CAGR
Div 164,150 164,150 164,150 164,150 152,425 140,700 140,700 2.60%
Div Payout % 104.63% 98.79% 101.28% 86.95% 123.02% 118.76% 100.33% -
Equity
30/06/19 30/06/18 30/06/17 30/06/16 30/06/15 30/06/14 30/06/13 CAGR
Net Worth 715,224 736,330 712,879 722,259 691,775 705,844 705,844 0.22%
NOSH 234,500 234,500 234,500 234,500 234,500 234,500 234,500 0.00%
Ratio Analysis
30/06/19 30/06/18 30/06/17 30/06/16 30/06/15 30/06/14 30/06/13 CAGR
NP Margin 11.75% 12.69% 12.63% 15.26% 10.84% 9.33% 11.55% -
ROE 21.94% 22.57% 22.73% 26.14% 17.91% 16.79% 19.87% -
Per Share
30/06/19 30/06/18 30/06/17 30/06/16 30/06/15 30/06/14 30/06/13 CAGR
RPS 569.60 558.23 547.39 527.58 487.38 541.65 517.79 1.60%
EPS 66.90 70.86 69.11 80.51 52.84 50.52 59.80 1.88%
DPS 70.00 70.00 70.00 70.00 65.00 60.00 60.00 2.60%
NAPS 3.05 3.14 3.04 3.08 2.95 3.01 3.01 0.22%
Adjusted Per Share Value based on latest NOSH - 234,500
30/06/19 30/06/18 30/06/17 30/06/16 30/06/15 30/06/14 30/06/13 CAGR
RPS 569.60 558.23 547.39 527.58 487.38 541.65 517.79 1.60%
EPS 66.90 70.86 69.11 80.51 52.84 50.52 59.80 1.88%
DPS 70.00 70.00 70.00 70.00 65.00 60.00 60.00 2.60%
NAPS 3.05 3.14 3.04 3.08 2.95 3.01 3.01 0.22%
Price Multiplier on Financial Quarter End Date
30/06/19 30/06/18 30/06/17 30/06/16 30/06/15 30/06/14 30/06/13 CAGR
Date 28/06/19 29/06/18 30/06/17 30/06/16 30/06/15 30/06/14 28/06/13 -
Price 149.10 147.50 85.00 76.52 71.50 67.00 67.00 -
P/RPS 26.18 26.42 15.53 14.50 14.67 12.37 12.94 12.45%
P/EPS 222.86 208.16 122.99 95.04 135.32 132.61 112.03 12.13%
EY 0.45 0.48 0.81 1.05 0.74 0.75 0.89 -10.73%
DY 0.47 0.47 0.82 0.91 0.91 0.90 0.90 -10.25%
P/NAPS 48.89 46.97 27.96 24.84 24.24 22.26 22.26 14.00%
Price Multiplier on Announcement Date
30/06/19 30/06/18 30/06/17 30/06/16 30/06/15 30/06/14 30/06/13 CAGR
Date 27/08/19 14/08/18 21/08/17 22/08/16 12/08/15 12/08/14 22/08/13 -
Price 149.10 147.20 84.58 78.76 71.92 67.70 67.54 -
P/RPS 26.18 26.37 15.45 14.93 14.76 12.50 13.04 12.31%
P/EPS 222.86 207.74 122.38 97.83 136.12 134.00 112.94 11.98%
EY 0.45 0.48 0.82 1.02 0.73 0.75 0.89 -10.73%
DY 0.47 0.48 0.83 0.89 0.90 0.89 0.89 -10.09%
P/NAPS 48.89 46.88 27.82 25.57 24.38 22.49 22.44 13.85%

PBT = Profit before Tax, NP = Net Profit, NP to SH = Net Profit Attributable to Shareholder, Div = Dividend, NP Margin = Net Profit Margin, ROE = Return on Equity, NOSH = Number of Shares, RPS = Revenue per Share, EPS = Earning Per Share, DPS = Dividend Per Share, NAPS = Net Asset Per Share, EOQ = End of Quarter, ANN = Announcement, P/RPS = Price/Revenue per Share, P/EPS = Price/Earning per Share, P/NAPS = Price/Net Asset per Share, EY = Earning Yield, DY = Dividend Yield.

NOSH is estimated based on the NP to SH and EPS. Div is an estimated figure based on the DPS and NOSH. Net Worth is an estimated figure based on the NAPS and NOSH.

Div Payout %, NP Margin, ROE, DY, QoQ ⃤ & YoY ⃤ figures in Percentage; RPS, EPS & DPS's figures in Cent; and NAPS's figures in Dollar.

All figures in '000 unless specified.

Discussions
Be the first to like this. Showing 0 of 0 comments
Post a Comment